Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
306results about How to "Inhibition of proliferative ability" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Total sesquiterpene lactone extract of centipeda minima, preparation method and application thereof
InactiveCN101732383AInhibition of proliferative abilityInhibition of tumor proliferationOrganic active ingredientsOrganic chemistrySilica gelTumor cells
The invention provides a total sesquiterpene lactone extract of centipeda minima, a preparation method and application thereof. The preparation method comprises the following steps: crushing dried total centipeda minima, and extracting centipeda minima volatile oil by a supercritical carbon dioxide extracting method; and enriching the centipeda minima volatile oil through macroporous adsorption resin column chromatography or silica gel column chromatography to obtain the total sesquiterpene lactone extract of the centipeda minima. According to the method, the total sesquiterpene lactone with effect of inhibiting tumor proliferation is extracted from Chinese medicament centipeda minima and is enriched for the first time; the extract is rich in short-leaf geraniin; the extract contains at least nine sesquiterpene lactone compounds, wherein the angelic acid centipeda minima and the isobutyric acid centipeda minima are new active sesquiterpene lactone compounds; by the preparation method, the yield is high; the method is suitable for industrialized production; and the extract has the effect of inhibiting tumor cell proliferation, and can be used for preparing various medicaments or health-care products with anti-tumor effect.
Owner:JINAN UNIVERSITY
A kind of monoclonal antibody of ap-2alpha and its application in the preparation of medicine for treating cervical cancer
ActiveCN111393525BInhibition of proliferative abilityImprove immune activityBacteriaImmunoglobulins against animals/humansAntiendomysial antibodiesCervical ca
Owner:湖南金朋医疗器械股份有限公司
NO donor type matrine derivative and preparation method and medical application thereof
ActiveCN103694238APrevent proliferationInhibition of proliferative abilityOrganic active ingredientsOrganic chemistryMatrineNo donors
The invention relates to the field of medical chemistry and pharmacotherapeutics, and particularly relates to an NO donor type matrine derivative and a preparation method thereof and application in pharmacy. The compounds have an anti-tumor effect and can be used for preparing anti-tumor medicines. The invention also relates to a preparation method of the compounds.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Environment-friendly textile printing pearlescent adhesive cement and preparation method and application thereof
InactiveCN102174747ARich graphic expression techniquesInhibition of proliferative abilityDyeing processAdhesive cementSpontaneous combustion
The invention discloses an environment-friendly textile printing pearlescent adhesive cement and a preparation method and application thereof. The adhesive cement comprises the following components in percentage by weight: 49 to 39 percent of environment-friendly ultra-soft adhesive, 15 to 25 percent of rutile silvery white pearlescent powder in the particle size range of between 5 and 25 microns, 15 to 25 percent of anatase silvery white pearlescent powder in the particle size range of between 10 and 60 microns, 4 to 6 percent of glycol, 1 to 2 percent of dispersing agent, 1 to 3 percent of leveling agent, 1 to 2 percent of mould-proof antibacterial auxiliary agent, 2 to 4 percent of nano negative ion far-infrared powder and 2 to 4 percent of thickening agent. The adhesive cement cannot block a screen during screen printing, has high weather resistance and has the obvious advantages of environment friendliness, no toxic hazard, high-temperature resistance, acid-base resistance, incapability of spontaneous combustion and combustion supporting, high oxidation resistance, high covering power and the like which are obviously distinguished from those of the common dye and pigment.
Owner:SUZHOU UNIV
Application of flavonoids compounds to breast cancer resistance
ActiveCN102335165AInhibition of proliferative abilityOrganic active ingredientsAntineoplastic agentsStructural formulaHuman breast
The invention discloses application of four kinds of known flavonoids compounds to treatment of breast cancers. The four kinds of known flavonoids are known compoundes obtained by separating fruit of sinopodophyllum emodi and have structures shown as structural formulas 1-4 in the specification. Experiments on the effect of the kinds of compounds on inhibiting human breast cancer cells show that the series of compounds have a favorable effect on inhibiting the proliferation of the breast cancer cells.
Owner:PEKING UNIV
Compound prescription of Chinese medicinal effective ingredients having anti-neovascularization synergetic effect
ActiveCN1965830AStrong antiangiogenic pharmacological activityInhibition of proliferative abilityAntineoplastic agentsHeterocyclic compound active ingredientsDiseaseAdditive ingredient
The invention relates to a traditional medicine with vessel growth resistance function, wherein it is formed by matrine and kukoline at 1:0.05-1 ratio. It can improve treatment effect and reduce toxicity, on atrophic arthritis, cancer, etc.
Owner:TSINGHUA UNIV
AP-2alpha monoclonal antibody and application to preparation of drugs for treating cervical cancers
ActiveCN111393525AInhibition of proliferative abilityImprove immune activityBacteriaImmunoglobulins against animals/humansAntiendomysial antibodiesCervical ca
The present invention relates to an AP-2alpha monoclonal antibody and an application to preparation of drugs for treating cervical cancers. The monoclonal antibody has the relatively good cervical cancer cell proliferation inhibiting effect, thereby having the wide application prospect.
Owner:湖南金朋医疗器械股份有限公司
Recombinant adeno-associated virus as well as construction method and application thereof
InactiveCN105586320AImprove submission efficiencyEnhance antigen presentationTumor rejection antigen precursorsTumor specific antigensWilms' tumorGene
The invention relates to a recombinant adeno-associated virus. The recombinant adeno-associated virus is formed by inserting a tumor antigen gene into a shuttle expression vector pAAV-MCS. The invention also provides a construction method and an application of the recombinant adeno-associated virus. According to the invention, the recombinant adeno-associated virus carrying a tumor-associated antigen gene is utilized for infecting DC cells and expresses tumor-associated antigen protein in the DC cells, and a PD-1 gene is also combined for silencing CTL cells in the application method of the recombinant adeno-associated virus.
Owner:厚朴生物科技(苏州)有限公司
Fully human anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody and preparation method as well as application thereof
ActiveCN102167740AAntibody affinity is highInhibition of proliferative abilityDigestive systemImmunoglobulins against growth factorsPhage antibodiesAntiendomysial antibodies
The invention relates to the field of biotechnology, in particular to a fully human anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody and a preparation method as well as application thereof. In the invention, a large-capacity natural human phage antibody library is constructed; a fully human anti-VEGF antibody 11A7 is screened from the library; an amino acid sequence of a heavy chain variable region of the antibody is shown as SEQ ID NO: 6; and an amino acid sequence of a light chain variable region of the antibody is shown as SEQ ID NO: 8. The invention also discloses the preparation method of the 11A7 antibody, a nucleotide sequence encoding the 11A7 antibody, a nucleic acid sequence-containing expression vector and a host cell. Compared with a humanized antibody bevacizumab, the 11A7 antibody has higher affinity of the antibody and higher capacity of suppressing proliferation of tumor cells and can be used for obviously suppressing growth of tumors and preparing anti-tumor medicaments.
Owner:YUEHAI BIOPHARM SHAOXING LTD SHAOXING CITY
Use of ganoderic acid T and ganoderic and Me in tumour growth or proliferation inhibitor
InactiveCN1709264AInhibit tumor cell proliferationInhibition of infinityOrganic active ingredientsTumor growthToxicity
Owner:EAST CHINA UNIV OF SCI & TECH +1
Compound of CDK7 small-molecule inhibitor, and application thereof
ActiveCN112010828AInhibition of proliferative abilityImprove proliferative abilityOrganic chemistryAmide active ingredientsPharmaceutical medicinePerylene derivatives
The invention belongs to the field of pharmacy and tumor diagnosis and treatment, and particularly relates to a compound serving as a cyclin-dependent kinase 7 (CDK7) inhibitor, and application of thecompound in treatment of proliferative diseases such as cancers including breast cancer, ovarian cancer, colon cancer, liver cancer, lung cancer and glioma. The CDK7 small-molecule inhibitor is a compound with the structural general formulas (I)-(X), or a stereoisomer, a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, isotope labeled derivative or prodrug thereof. The small-molecule inhibitor provided by the invention is wide in anticancer spectrum; the compound has a good growth inhibition effect on various cancer cells such as liver cancer, stomach cancer, colorectal cancer, ovarian cancer, glioma, lung cancer and the like, provides an effective drug for preventing or treating proliferative diseases, especially cancers, in the aspects of structure and action mechanism, and has a good application prospect.
Owner:中国医科大学
Flavanone derivatives, preparation method and use thereof
InactiveCN101602754AHas antitumor activityInhibition of proliferative abilityOrganic active ingredientsOrganic chemistryDiseaseAcetophenone
The invention relates to polyphenol substances, a synthesis method and use thereof, in particular to flavanone derivatives, a preparation method and use thereof, which solves the problem that the prior natural flavanone compounds are difficult to extract, not easy to obtain and incapable of extensive use. The compounds have a structure (as above), wherein R1, R2 and R3 are selected from hydrogen, 1 to 8 carbonic alkyl groups, halogen, nitro group, 1 to 8 carbonic alkoxy or amino groups respectively; R4 and R5 can be selected from 1 to 8 carbonic alkyl groups, 1 to 8 alkoxy or alkenyl groups respectively; and the compounds are obtained through the reaction of compound 6-hydroxy-2,4-hydroxy acetophenone substances and aromatic aldehydes or heterocyclic aldehyde substances in polyalcohol solvent by taking high-boiling-point acid as a catalyst, and can be applied to the preparation of medicaments for resisting tumors and cardiovascular and cerebrovascular diseases. The flavanone derivatives have the activity of resisting tumors and inhibiting the cardiovascular and cerebrovascular diseases, thereby opening up a new way for preparing the medicaments and bringing new breakthroughs for the medicament field. Moreover, the synthesis method has the advantages of mild conditions and easy operation.
Owner:李青山 +2
Long noncoding RNA SNHG15 and application thereof in preparation of cancer diagnosis and treatment drugs
InactiveCN108707668APrevent invasionInhibit migrationMicrobiological testing/measurementCancers diagnosisColorectal cancer cell line
The invention belongs to the technical field of genetic engineering, and discloses long noncoding RNA SNHG15 and application thereof in preparation of cancer diagnosis and treatment drugs. Cancers include colorectal cancer, breast cancer, kidney cancer and the like. Expression of the long noncoding RNA SNHG15 in tumor tissues of patients suffering from the colorectal cancer, the breast cancer andthe kidney cancer is up-regulated. The patients with highly-expressed long noncoding RNA SNHG15 have poor prognosis. Through expression knock-down of the long noncoding RNA SNHG15 in colorectal cancercell lines, invasion, migration and multiplication capabilities of cells can be inhibited, and drug susceptibility of colorectal cancer cell lines to antitumor drugs including gemcitabine and cis-platinum can be improved.
Owner:PEKING UNIV
Applications of CIZI gene and relevant medicines
ActiveCN103421886APrevent proliferationGrowth inhibitionMicrobiological testing/measurementGenetic material ingredientsLentivirusTumor cell apoptosis
The invention discloses applications of CIZI gene and relevant medicines, discloses applications of CIZI gene in preparation or screening of oncological therapeutic medicines of liver cancer, lung cancer, breast carcinoma or glioma, further constructs separated nucleic acid molecules, CIZI gene interference nucleic acid construction bodies and CIZI gene interference lentivirus which can decrease expression of CIZI gene in tumor cells and discloses applications thereof. The nucleic acid molecules, nucleic acid construction bodies or CIZI gene interference lentivirus can inhibit the expression of the CIZI gene specifically. Especially, lentivirus can infect target cells efficiently, the expression of the CIZI gene in the target cells is inhibited efficiently, furthermore the growth of the tumor cells is inhibited, the apoptosis of the tumor cells is promoted, and the applications of CIZI gene and the relevant medicines are significant in oncotherapy.
Owner:SHANGHAI JI KAI GENE TECH CO LTD
Use of human zfx gene and related medicines
ActiveCN102277434AReduced expression levelInhibition of proliferative abilityMicrobiological testing/measurementGenetic material ingredientsHuman tumorNucleic acid sequencing
The invention discloses the use of human ZFX gene and related medicines. The invention discloses the application of human ZFX gene in tumor treatment, tumor diagnosis and medicine preparation. The present invention further constructs human ZFX gene small molecule interference RNA, human ZFX gene interference nucleic acid construct, human ZFX gene interference lentivirus and discloses their applications. The siRNA provided by the present invention or the nucleic acid construct containing the siRNA sequence, and the lentivirus can specifically inhibit the expression of the human ZFX gene, especially the lentivirus, which can efficiently infect target cells and efficiently inhibit the expression of the ZFX gene in the target cells , and then inhibit the growth of tumor cells and promote the apoptosis of tumor cells, which is of great significance in tumor therapy.
Owner:SHANGHAI GENECHEM
Nitric oxide donor type coumarin derivatives, preparation methods therefor and medicinal use of nitric oxide donor type coumarin derivatives
ActiveCN106946868APrevent proliferationInhibition of proliferative abilityOrganic active ingredientsOrganic chemistryNitric oxideCoumarin
The invention relates to the fields of pharmacochemistry and pharmacotherapeutics and particularly relates to nitric oxide donor type coumarin derivatives, preparation methods therefor and an application of the nitric oxide donor type coumarin derivatives. The compounds play a role in resisting tumors and can be applied to the preparation of antitumor drugs.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Anti-PRRSV (porcine reproductive and respiratory syndrome virus) microRNA (ribonucleic acid)-like virus small RNA sequence and application and detection method thereof
ActiveCN106399313AInhibition of replicationInhibition of proliferative abilityMicrobiological testing/measurementDNA/RNA fragmentationHighly pathogenicProtein secondary structure
The invention discloses an anti-PRRSV (porcine reproductive and respiratory syndrome virus) microRNA (ribonucleic acid)-like virus small RNA sequence and an application and detection method thereof. A sequence of a mature body of PRRSV-vsRNA1 and a precursor sequence as well as a secondary structure with encoding of PRRSV-vsRNA1 are disclosed. The inhibiting effect of the PRRSV-vsRNA1 in porcine alveolar macrophages (PAMs) infected by PRRSV and highly pathogenic strains of PRRSV is verified through different methods. The anti-PRRSV microRNA-like virus small RNA sequence can specifically target PRRSV viral non-structure protein 2(Nsp2), and function of proliferation of the PRRSV in PAMs is inhibited. The PRRSV-vsRNA1 is expected to be novel medicine for preventing and controlling PRRS, and the effective method is provided for prevention and control of the PRRSV.
Owner:NORTHWEST A & F UNIV
Anti-VEGFR2 human source nano antibody NTV1 and preparation method therefor and use thereof
InactiveCN105085677AImprove bindingGood antitumor activityImmunoglobulins against growth factorsAntibody ingredientsComplementarity determining regionAntitumor activity
The invention discloses an anti-VEGFR2 human source nano antibody NTV1 which comprises a frame region and a complementarity-determining region, wherein the nano antibody has an amino acid sequence shown in SEQ ID NO: 1. The invention further provides a preparation method for the anti-VEGFR2 human source nano antibody NTV1. The preparation method comprises the following steps: a, screening a nano antibody combined with VEGFR2 by adopting a phage display technology; b, carrying out expression and purification of the nano antibody; and c, determining the interaction between an antigen and the antibody by adopting an AlphaScreen technology to further screen the antibody with the highest affinity . The human source nano antibody NTV1 with higher affinity and good anti-tumor activity is obtained. The VEGFR2 nano antibody egg white which is high in affinity and stable and uniform is obtained by expression and optimization, a human source anti-VEGFR3 nano antibody drug is successfully developed, and a novel field of drug research and development of a targeted VEGFR2 antibody is opened up.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Method for extracting C15H18O5 from Cichorium glandulosum Boiss.et Hout and application of C15H18O5
InactiveCN103804334AEasy to prepareLow costOrganic active ingredientsOrganic chemistrySephadexDistillation
The invention relates to a method for separating and extracting C15H18O5 from Cichorium glandulosum Boiss.et Hout and use of C15H18O5 the English name of which is 11B, 13-Dihydrolacurin. The method is characterized by comprising the following steps: soaking the root of Cichorium glandulosum Boiss.et Hout by ethanol; collecting the percolate by a percolation method; obtaining a thick extract by a reduced pressure distillation device; passing the extract through a silicagel column, an octadecylsilyl column and a Sephadex LH-20 column; eluting; and drying the eluant by the reduced pressure distillation device to obtain dry powder which is the monomer C15H18O5, the English name of which is 11B, 13-Dihydrolacurin. The compound has the effect of preventing anti-hepatic fibrosis, namely, the compound inhibits activating and proliferating effect of hepatic stellate cells, so that the C15H18O5 with the English name of 11B, 13-Dihydrolacurin can be used as a lead compound for preventing anti-hepatic fibrosis.
Owner:SHIHEZI UNIVERSITY
5-hydroxy-2'-nitroaurone or 5-hydroxy-4'-nitroaurone derivatives and application thereof
ActiveCN105037305AAntiproliferative activityInhibition of proliferative abilityOrganic active ingredientsNervous disorderWilms' tumorInhibitory effect
The invention discloses a 5-hydroxy-2'-nitroaurone or 5-hydroxy-4'-nitroaurone derivatives and application thereof, wherein the derivatives are a compound represented as the formula (I), an isomer or a pharmaceutically acceptable salt thereof. The compound is excellent in inhibition activity on endothelial cells and tumor cells comprising A549, Bel-74021 and MCF-7, and is excellent in inhibition effects on migration and invasion of the tumor cell A549.
Owner:NANJING UNIV OF TECH
Applications and correlated medicament of human STIM1 gene
ActiveCN102433383AReduced expression levelInhibition of proliferative abilityMicrobiological testing/measurementGenetic material ingredientsSTIM1 geneTumor cell apoptosis
The invention discloses applications a correlated medicament of a human STIM1 gene. The invention discloses applications of the human STIM1 gene in tumor treatment, tumor diagnosis and medicament preparation. The invention also further constructs a human STIM1 gene small-interfering ribonucleic acid (siRNA), a human STIM1 gene interfering nucleic acid construct, a human STIM1 gene interfering slow virus and applications thereof. The siRNA or nucleic acid construct and slow virus comprising the siRNA sequence can specifically inhibit the expression of the human STIM1 gene, particularly, the slow virus can infect a target cell efficiently so as to effectively inhibit the expression of STIM1 gene in the target cell, thus further inhibiting the growth of tumor cells and promoting apoptosis of the tumor cells. Therefore, the human STIM1 gene has important significance in tumor treatment.
Owner:SHANGHAI GENBASE BIOTECH CO LTD
Application of bone marrow mesenchymal stem cells combined with monoclonal antibodies in cancer treatment
InactiveCN112940126AInhibition of proliferative abilityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesCancer cell
The invention relates to application of bone marrow mesenchymal stem cells combined with monoclonal antibodies in cancer treatment. Monoclonal antibodies specifically aiming at the liver cancer are obtained through screening, the antibodies have a good effect of inhibiting proliferation of liver cancer cells Huh-7 and HepG2 at the same time, meanwhile it is confirmed in a mouse model test that the monoclonal antibodies have a good effect of inhibiting proliferation of tumors in a mouse body, and the antibodies and mesenchymal stem cells are combined for treating liver cancer to generate a synergistic effect, so that the antibodies have a relatively good application prospect.
Owner:北京广未生物科技有限公司
Neogambogic acid derivative, preparation method thereof and pharmaceutical application
InactiveCN103304575APrevent proliferationInhibition of proliferative abilityOrganic active ingredientsOrganic chemistryNeogambogic acidMedicinal chemistry
The invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular relates to a neogambogic acid derivative, as well as a preparation method and a pharmaceutical application thereof. The neogambogic acid derivative has an anti-tumor function and can be used for preparing anti-tumor pharmaceuticals. The invention further relates to the preparation method of the neogambogic acid derivative.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Albumin variant having anti-angiogenesis activity and preparation method thereof
ActiveCN101875693BRetain molecular structureImprove functionalityFungiPeptide/protein ingredientsHuman albuminIn vivo
The invention belongs to the technical field of biomedicine, in particular to the technical field of an albumin medicament. In order to solve the technical problems of short half-life period in vivo and high use level of the existing ATWLPPR peptide, the invention provides an albumin variant. The albumin variant is obtained by mutating a KEQLK peptide section at the tail end of albumin C to a WLPPR peptide section. The albumin variant completely reserves the functions of human albumin and simultaneously has a new ATWLPPR sequence function. Experiments in vitro prove that the albumin variant can obviously inhibit the proliferation and migration of vascular endothelial cells induced by VEGF (Vascular Endothelial Growth Factor) in vitro, and the efficiency of the albumin variant corresponds to that of small peptide. Moreover, when the albumin variant is injected into animals, the efficiency of inhibiting the cornea angiogenesis functions of rabbits is 40-60 times higher than that of the small peptide with the same concentration. The albumin variant can be used as a novel anti-angiogenesis medicament with high efficiency.
Owner:CHENGDU ZEN BIOSCI
Holothuria moebii saponin A, and preparation and application thereof
InactiveCN104045682AInhibition of proliferative abilityOrganic active ingredientsSteroidsHuman brainChromatographic separation
The invention provides Holothuria moebii saponin A. The Holothuria moebii saponin A is prepared by separating total Holothuria moebii saponin from the marine invertebrate Holothuria moebii through percolation, extraction and reverse phase silica gel (ODS) column chromatography, then carrying out reverse phase silica gel column chromatographic separation and carrying out pressure-reduced concentration. The Holothuria moebii saponin A provided by the invention can substantially inhibit proliferation of a plurality of cells like rat brain glioma C6 and human brain glioma U87-MG, U251 and SHG-44, induce tumor cell apoptosis, reduce protein expression of a plurality of key enzymes in characteristic metabolism process of tumor cells and has a unique multi-target anti-glioma characteristic. Thus, the Holothuria moebii saponin A can be applied in preparation of drugs used for treating brain glioma. The chemical structural formula of the Holothuria moebii saponin A is described in the specification.
Owner:ZHEJIANG UNIV
Method for screening protein biological markers related to hepatic stellate cell activation and hepatic fibrosis
InactiveCN102618613AAvoid stickingAbility to inhibit migrationMaterial analysis by electric/magnetic meansPeptide preparation methodsHepatic stellate cell activationStatics
The invention discloses a method for screening protein biological markers related to hepatic stellate cell activation and hepatic fibrosis. The method comprises the preparation of the automatic aviation models of hepatic stellate cells subjected to isolation culture and in vitro culture and the preparation of static and activated hepatic stellate cell protein samples. The invention has the advantages that the method is simple, and the operation is easy.
Owner:NANTONG UNIVERSITY
Simulated lactic acid bacterium flavored vegetarian sausage
InactiveCN106942391APromote decompositionPromote calcificationCheese manufactureAdditive ingredientVacuum pack
The present invention relates to a simulated lactic acid bacterium flavored vegetarian sausage. The vegetarian sausage mainly comprises the following components: textured soybean proteins, water, soybean oil and lactic acid bacteria. The simulated lactic acid bacterium flavored vegetarian sausage is prepared by vegetarian meat stirring, compound ingredient stirring, lactic acid bacterium inoculating, fermenting, sausage filling, shaping and cooking, cooling and sausage casing stripping, vacuum packaging, and sterilizing. The proteins of soybeans in the prepared simulated lactic acid bacterium flavored vegetarian sausage contains isoflavones, the lactic acid bacteria promote absorptions of nutrients of proteins, monosaccharide, calcium, magnesium, etc., and the vegetarian sausage produces a large amount of beneficial substances of vitamin B groups, etc., inhibits cholesterol absorption, lowers blood lipids and blood pressure, has good chewiness, is rich in flavor and full and life-like in appearance, and has shape characteristics of meat products of the sausages.
Owner:深圳齐善食品有限公司
Application and related pharmaceuticals of human ubiquitin-protein ligase 138 (RNF138) gene
ActiveCN103305596AReduced expression levelInhibition of proliferative abilityMicrobiological testing/measurementGenetic material ingredientsDrugOligonucleotide
The invention discloses an application related pharmaceuticals of a human ubiquitin-protein ligase 138 (RNF138) gene and particularly discloses an application of the human RNF138 gene in tumor treatment and pharmaceutical preparation. The invention further structures an oligonucleotide molecule, a human RNF138 gene interference lentiviral vector and a human RNF138 gene interference lentivirus for human RNF138 gene separation and discloses applications thereof. The oligonucleotide molecule or the lentiviral vector and the lentivirus containing an oligonucleotide molecule sequence provided by the invention can specifically inhibit the human RNF138 gene expression, and particularly, the lentivirus can efficiently infect target cells, effectively inhibit the RNF138 gene expression of the target cells, further inhibit the tumor cell growth, promote the tumor cell apoptosis and have an important meaning on tumor treatment.
Owner:SHANGHAI JI KAI GENE TECH CO LTD
Application of long-chain non-coding RNA in preparing preparation for inhibiting tumor cell migration
ActiveCN108236724AInhibit transferInhibition of proliferative abilityOrganic active ingredientsGenetic material ingredientsMechanism of actionLong chain
Owner:FUDAN UNIV
2,3-dihydro-4(1H)- quinazolone derivative and application thereof
InactiveCN101935318AInhibition of proliferative abilityOrganic active ingredientsSenses disorderDiseaseMedicine
The invention discloses a substituted 2,3-dihydro-4(1H)- quinazolone derivative shown in the formula I, pharmaceutically acceptable salt or solvate and a drug composite containing the same and application thereof. The compound has very good effect of restraining vascular endothelial cell proliferation. The compound, the pharmaceutically acceptable salt or solvate or the drug composite containing the same can be used for drugs requiring to restraining angiogenesis diseases and / or cytotoxicity exerting diseases.
Owner:SHANGAI PHARMA GRP CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com